JP2020505932A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020505932A5 JP2020505932A5 JP2019542407A JP2019542407A JP2020505932A5 JP 2020505932 A5 JP2020505932 A5 JP 2020505932A5 JP 2019542407 A JP2019542407 A JP 2019542407A JP 2019542407 A JP2019542407 A JP 2019542407A JP 2020505932 A5 JP2020505932 A5 JP 2020505932A5
- Authority
- JP
- Japan
- Prior art keywords
- immune effector
- effector cell
- chimeric antigen
- antigen receptor
- cytoplasmic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004027 cell Anatomy 0.000 claims description 95
- 239000012642 immune effector Substances 0.000 claims description 88
- 229940121354 immunomodulator Drugs 0.000 claims description 88
- 229920001184 polypeptide Polymers 0.000 claims description 77
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 77
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 77
- 150000001875 compounds Chemical class 0.000 claims description 67
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 46
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 claims description 37
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 claims description 37
- 102000004169 proteins and genes Human genes 0.000 claims description 37
- 108090000623 proteins and genes Proteins 0.000 claims description 37
- 230000001086 cytosolic effect Effects 0.000 claims description 36
- 230000001225 therapeutic effect Effects 0.000 claims description 22
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 claims description 16
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 claims description 16
- 230000004068 intracellular signaling Effects 0.000 claims description 9
- 108020001756 ligand binding domains Proteins 0.000 claims description 9
- 230000028993 immune response Effects 0.000 claims description 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 6
- 206010052015 cytokine release syndrome Diseases 0.000 claims description 5
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 4
- 230000004913 activation Effects 0.000 claims description 4
- 239000012636 effector Substances 0.000 claims description 4
- 102100027207 CD27 antigen Human genes 0.000 claims description 3
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims description 3
- 101000941994 Homo sapiens Protein cereblon Proteins 0.000 claims description 3
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 3
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- 102100032783 Protein cereblon Human genes 0.000 claims description 3
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 3
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 3
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims description 3
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims description 3
- 230000000735 allogeneic effect Effects 0.000 claims description 3
- 239000000427 antigen Substances 0.000 claims description 3
- 102000036639 antigens Human genes 0.000 claims description 3
- 108091007433 antigens Proteins 0.000 claims description 3
- 230000001363 autoimmune Effects 0.000 claims description 3
- 239000003446 ligand Substances 0.000 claims description 3
- 230000011664 signaling Effects 0.000 claims description 3
- 239000000439 tumor marker Substances 0.000 claims description 3
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 238000000034 method Methods 0.000 description 4
- 230000002411 adverse Effects 0.000 description 2
- 230000000593 degrading effect Effects 0.000 description 2
- 230000002939 deleterious effect Effects 0.000 description 2
- 230000002222 downregulating effect Effects 0.000 description 2
- 229940126062 Compound A Drugs 0.000 description 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762456649P | 2017-02-08 | 2017-02-08 | |
| US62/456,649 | 2017-02-08 | ||
| US201762457124P | 2017-02-09 | 2017-02-09 | |
| US62/457,124 | 2017-02-09 | ||
| PCT/US2018/017464 WO2018148440A1 (en) | 2017-02-08 | 2018-02-08 | Regulating chimeric antigen receptors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020505932A JP2020505932A (ja) | 2020-02-27 |
| JP2020505932A5 true JP2020505932A5 (enExample) | 2021-03-25 |
| JP7227912B2 JP7227912B2 (ja) | 2023-02-24 |
Family
ID=63107041
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019542407A Active JP7227912B2 (ja) | 2017-02-08 | 2018-02-08 | キメラ抗原受容体の調節 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11311609B2 (enExample) |
| EP (2) | EP3580212A4 (enExample) |
| JP (1) | JP7227912B2 (enExample) |
| CN (1) | CN111386263A (enExample) |
| AU (1) | AU2018219289A1 (enExample) |
| CA (1) | CA3053006C (enExample) |
| WO (1) | WO2018148440A1 (enExample) |
Families Citing this family (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10039809B2 (en) | 2013-12-18 | 2018-08-07 | The California Institute For Biomedical Research | Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof |
| EP3331906A1 (en) * | 2015-08-06 | 2018-06-13 | Dana-Farber Cancer Institute, Inc. | Tunable endogenous protein degradation |
| WO2017180587A2 (en) | 2016-04-11 | 2017-10-19 | Obsidian Therapeutics, Inc. | Regulated biocircuit systems |
| WO2018118598A1 (en) | 2016-12-23 | 2018-06-28 | Arvinas, Inc. | Compounds and methods for the targeted degradation of fetal liver kinase polypeptides |
| JP7679173B2 (ja) | 2016-12-23 | 2025-05-19 | アルビナス・オペレーションズ・インコーポレイテッド | Ｒａｆ（急速進行性線維肉腫）ポリペプチドの標的分解のための化合物および方法 |
| RU2019121527A (ru) | 2016-12-23 | 2021-01-15 | Эрвинэс Оперейшнс, Инк. | Химерные молекулы, нацеливающиеся на протеолиз egfr, и связанные с ними способы применения |
| US11173211B2 (en) | 2016-12-23 | 2021-11-16 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides |
| CN117551089A (zh) | 2017-01-26 | 2024-02-13 | 阿尔维纳斯运营股份有限公司 | 雌激素受体蛋白水解调节剂及相关使用方法 |
| CN110621322A (zh) * | 2017-02-08 | 2019-12-27 | 达纳-法伯癌症研究所有限公司 | 用异双功能性化合物进行的可调节的内源性蛋白质降解 |
| WO2019067425A1 (en) | 2017-09-26 | 2019-04-04 | The Trustees Of The University Of Pennsylvania | COMPOSITIONS AND METHODS FOR TREATING CARDIAC DISEASE BY REDIRECTED T-CELL IMMUNOTHERAPIES |
| CA3079407A1 (en) | 2017-10-18 | 2019-04-25 | Novartis Ag | Compositions and methods for selective protein degradation |
| JP7720698B2 (ja) | 2018-04-04 | 2025-08-08 | アルビナス・オペレーションズ・インコーポレイテッド | タンパク質分解の調節因子および関連する使用方法 |
| JP7297053B2 (ja) | 2018-08-20 | 2023-06-23 | アルビナス・オペレーションズ・インコーポレイテッド | 神経変性疾患を治療するためのｅ３ユビキチンリガーゼ結合活性を有するキメラ（ｐｒｏｔａｃ）化合物を標的とし、アルファ－シヌクレインタンパク質を標的とするタンパク質分解 |
| GB201814203D0 (en) * | 2018-08-31 | 2018-10-17 | King S College London | Engineered regulatory t cell |
| EP3846800A4 (en) | 2018-09-04 | 2022-08-24 | C4 Therapeutics, Inc. | Compounds for the degradation of brd9 or mth1 |
| EP3856190A4 (en) * | 2018-09-27 | 2022-09-21 | Dana Farber Cancer Institute, Inc. | DEGRADATION OF FAK OR FAK AND ALK BY CONJUGATION OF FAK AND ALK INHIBITORS WITH E3-LIGASE LIGANDS AND METHODS OF USE |
| WO2020077278A1 (en) * | 2018-10-12 | 2020-04-16 | The Scripps Research Institute | Compounds and methods for dcaf-mediated protein degradation |
| CN112888460A (zh) * | 2018-10-16 | 2021-06-01 | 达纳-法伯癌症研究所有限公司 | Lrkk2的野生型及突变型的降解剂 |
| GB201816839D0 (en) * | 2018-10-16 | 2018-11-28 | Glaxosmithkline Ip Dev Ltd | Novel control switch |
| EP3873539A4 (en) * | 2018-10-31 | 2023-01-18 | The Children's Hospital of Philadelphia | LYMPH-BASED T-CELLS FOR DIAGNOSTIC AND THERAPEUTIC USE |
| CN109293631B (zh) * | 2018-11-30 | 2020-05-08 | 常州制药厂有限公司 | 3-氨基-n-(2，6-二氧代-3-哌啶基)-邻苯二甲酰亚胺化合物的制备方法 |
| EP3908291A4 (en) * | 2019-01-07 | 2023-01-11 | Dana-Farber Cancer Institute, Inc. | VON HIPPEL-LINDAU (VHL) E3 UBIQUITIN LIGASE RECRUITMENT AGENTS FOR FKBP12 SMALL MOLECULES DEGRADATION AND USES IN DTAG SYSTEMS |
| AU2020218546A1 (en) * | 2019-02-08 | 2021-09-09 | Dna Twopointo Inc. | Transposon-based modifications of immune cells |
| US12419913B2 (en) | 2019-02-08 | 2025-09-23 | Dna Twopointo, Inc. | Modification of CAR-T cells |
| CN113710697A (zh) * | 2019-03-15 | 2021-11-26 | 美国政府(由卫生和人类服务部的部长所代表) | 嵌合衔接子和激酶信号传导蛋白及其在免疫疗法中的用途 |
| US20230093099A1 (en) * | 2019-04-02 | 2023-03-23 | Cullgen (Shanghai), Inc. | Compounds and methods of treating cancers |
| BR112021019669A2 (pt) | 2019-04-12 | 2021-12-07 | C4 Therapeutics Inc | Composto, composição farmacêutica, método para tratar um transtorno, composto para uso na produção de um medicamento, e, uso de um composto no tratamento de um transtorno |
| EP3962480A4 (en) * | 2019-05-01 | 2023-06-07 | Nemucore Medical Innovations, Inc. | DEGRADATION OF AURORAKINASE (AURK) BY CONJUGATION OF AURK INHIBITORS WITH E3 LIGASE LIGAND |
| CN114206853A (zh) * | 2019-06-19 | 2022-03-18 | 里邦医疗公司 | 用于治疗的parp14的靶向蛋白质降解 |
| CN114867727B (zh) | 2019-07-17 | 2025-02-21 | 阿尔维纳斯运营股份有限公司 | Tau蛋白靶向化合物及相关使用方法 |
| CN114761036B (zh) | 2019-09-23 | 2025-09-30 | 宾夕法尼亚大学董事会 | 与小鼠和人成纤维细胞激活蛋白(fap)交叉反应的抗犬成纤维细胞激活蛋白单克隆抗体 |
| AU2020353000A1 (en) | 2019-09-23 | 2022-04-07 | The Trustees Of The University Of Pennsylvania | Disrupting tumor tissues by targeting fibroblast activation protein (FAP) |
| CA3154386A1 (en) | 2019-10-17 | 2021-04-22 | Michael Berlin | Bifunctional molecules containing an e3 ubiquitine ligase binding moiety linked to a bcl6 targeting moiety |
| WO2021080427A1 (en) * | 2019-10-23 | 2021-04-29 | Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis | Chimeric polypeptide for regulating immune cells |
| EP4077680A4 (en) * | 2019-12-17 | 2024-01-10 | Orionis Biosciences, Inc. | DETECTION OF NEW DEGRADATION-RELATED INTERACTIONS |
| PE20221724A1 (es) | 2019-12-20 | 2022-11-04 | C4 Therapeutics Inc | Compuestos de isoindolinona e indazol para la degradacion del receptor del factor de crecimiento epidermico (egfr) |
| PE20230113A1 (es) * | 2020-01-16 | 2023-01-27 | Genmab As | Formulaciones de anticuerpos anti-cd38 y usos de las mismas |
| EP4126068A4 (en) * | 2020-03-31 | 2024-12-04 | Orum Therapeutics Inc. | CONJUGATES |
| KR20230040331A (ko) | 2020-07-21 | 2023-03-22 | 알로젠 테라퓨틱스 인코포레이티드 | 강화된 신호 전달 및 활성을 갖는 키메라 항원 수용체 및 이의 용도 |
| US12180193B2 (en) | 2020-08-28 | 2024-12-31 | Arvinas Operations, Inc. | Accelerating fibrosarcoma protein degrading compounds and associated methods of use |
| CN112194726B (zh) * | 2020-09-02 | 2023-06-23 | 沣潮医药科技（上海）有限公司 | 用于病理性蛋白聚集物清除的嵌合抗原受体及其应用 |
| MX2023003114A (es) | 2020-09-23 | 2023-03-23 | St Jude Childrens Res Hospital Inc | Analogos de n-(2-(2,6-dioxopiperidin-3-il)-1,3-dioxoisoindolin-5-i l)arilsulfonamida sustituidos como moduladores de la proteina cereblon. |
| CN116323570B (zh) * | 2020-09-30 | 2025-02-11 | 上海睿跃生物科技有限公司 | 治疗疾病的化合物和方法 |
| CN116615429A (zh) * | 2020-10-14 | 2023-08-18 | 珃诺生物医药科技(杭州)有限公司 | 用于靶向蛋白降解的方法和组合物 |
| US20240124465A1 (en) * | 2020-12-18 | 2024-04-18 | St. Jude Children's Research Hospital | Molecules and methods related to treatment of disorders associated with jak-2 signaling dysfunction |
| CN113234162B (zh) * | 2020-12-24 | 2022-05-13 | 四川大学华西医院 | 一种靶向cd133的嵌合抗原受体t细胞 |
| CN113024671B (zh) * | 2020-12-31 | 2022-05-24 | 北京艺妙神州医药科技有限公司 | 一种抗bcma的抗体及其应用 |
| CA3208313A1 (en) | 2021-01-13 | 2022-07-21 | Monte Rosa Therapeutics Ag | Isoindolinone compounds |
| AU2022259683A1 (en) | 2021-04-16 | 2023-10-19 | Arvinas Operations, Inc. | Modulators of bcl6 proteolysis and associated methods of use |
| KR20240017338A (ko) * | 2021-04-19 | 2024-02-07 | 난징 레전드 바이오테크 씨오., 엘티디. | 키메라 사이토카인 수용체 및 세포 요법에서 이의 용도 |
| AR125798A1 (es) | 2021-05-07 | 2023-08-16 | Kymera Therapeutics Inc | Degradadores cdk2 y usos de los mismos |
| KR20240032010A (ko) | 2021-06-09 | 2024-03-08 | 더 스크립스 리서치 인스티튜트 | 장기 지속형 이중 gip/glp-1 펩타이드 접합체 및 사용 방법 |
| US20250129047A1 (en) | 2021-07-04 | 2025-04-24 | Newave Pharmaceutical Inc. | Isoquinoline derivatives as mutant egfr modulators and uses thereof |
| KR20240053589A (ko) * | 2021-07-30 | 2024-04-24 | 하이노바 파마슈티컬스 인코포레이티드 | 이중 기능성 키메라 헤테로 고리 화합물 및 이의 안드로겐 수용체 분해제로서의 용도 |
| KR20240099267A (ko) * | 2021-10-18 | 2024-06-28 | 옵시디안 테라퓨틱스, 인크. | 폴리펩티드 페이로드의 기능/풍부성 및 전달의 조절을 위한 조성물 및 시스템 |
| WO2023070527A1 (zh) * | 2021-10-29 | 2023-05-04 | 上海鑫湾生物科技有限公司 | 一种条件控制的可剪接嵌合抗原受体分子及其应用 |
| EP4176895A1 (en) * | 2021-11-08 | 2023-05-10 | AvenCell Europe GmbH | Targeting modules against il13ra2 or her2 for use in combination with a chimeric antigen receptor |
| CN114874132B (zh) * | 2022-05-24 | 2023-06-06 | 无锡捷化医药科技有限公司 | 一种重组人受体蛋白fkbp12配体的制备方法 |
| WO2024015618A2 (en) * | 2022-07-15 | 2024-01-18 | St. Jude Children's Research Hospital, Inc. | Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione/2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione analogs as modulators of cereblon protein |
| US11957759B1 (en) | 2022-09-07 | 2024-04-16 | Arvinas Operations, Inc. | Rapidly accelerated fibrosarcoma (RAF) degrading compounds and associated methods of use |
| KR20250151412A (ko) | 2023-01-26 | 2025-10-21 | 아비나스 오퍼레이션스, 인코포레이티드 | 세레블론계 kras 분해 단백질 및 이와 관련된 용도 |
| CN116554353B (zh) * | 2023-04-28 | 2024-05-03 | 北京奇迈永华生物科技有限公司 | 一种假病毒高效感染人nk细胞及其他免疫细胞的方法 |
| WO2025006753A2 (en) | 2023-06-30 | 2025-01-02 | Merck Patent Gmbh | Heterobifunctional compounds for the degradation of kras protein |
| WO2025006783A2 (en) | 2023-06-30 | 2025-01-02 | Merck Patent Gmbh | Heterobifunctional compounds for the degradation of kras |
| KR20250017174A (ko) * | 2023-07-25 | 2025-02-04 | 한국화학연구원 | 면역세포의 조절 시스템 |
| WO2025122943A1 (en) * | 2023-12-08 | 2025-06-12 | Obsidian Therapeutics, Inc. | Compositions and methods for enhanced payload regulation using nuclear factor of activated t cells (nfat) response elements |
| CN119410598A (zh) * | 2024-09-27 | 2025-02-11 | 武汉大学 | 一种靶标识别系统及其应用 |
Family Cites Families (85)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4694778A (en) | 1984-05-04 | 1987-09-22 | Anicon, Inc. | Chemical vapor deposition wafer boat |
| US5278056A (en) | 1988-02-05 | 1994-01-11 | The Trustees Of Columbia University In The City Of New York | Retroviral packaging cell lines and process of using same |
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
| US5858358A (en) | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US5763590A (en) | 1991-10-11 | 1998-06-09 | Vertex Pharmaceuticals, Inc. | Isolation of an Mr 52,000 FK506 binding protein and molecular cloning of a corresponding human cDNA |
| US5686278A (en) | 1994-03-25 | 1997-11-11 | Indiana University Foundation | Methods for enhanced retrovirus-mediated gene transfer |
| US7175843B2 (en) | 1994-06-03 | 2007-02-13 | Genetics Institute, Llc | Methods for selectively stimulating proliferation of T cells |
| US5837533A (en) | 1994-09-28 | 1998-11-17 | American Home Products Corporation | Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent |
| US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
| US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
| FR2741066B1 (fr) | 1995-11-14 | 1997-12-12 | Rhone Poulenc Rorer Sa | Nouveaux agents de transfection et leurs applications pharmaceutiques |
| FR2743365A1 (fr) | 1996-01-10 | 1997-07-11 | Rhone Poulenc Rorer Sa | Derives de 5h,10h-imidazo(1,2-a)indolo(3,2-e)pyrazine-4-one, leur preparation et les medicaments les contenant |
| DE19605548A1 (de) | 1996-02-15 | 1997-09-04 | Boehringer Ingelheim Int | Zusammensetzung für die Transfektion höherer eukaryotischer Zellen |
| DE19607686A1 (de) | 1996-02-29 | 1997-09-04 | Chemicon Lab Gmbh | Neue metabolisierbare Lipopolyamine, deren Darstellung und Anwendung |
| EP1094114B1 (en) | 1998-07-01 | 2007-01-03 | Takara Bio Inc. | Gene transfer methods |
| US6566073B1 (en) | 1998-10-19 | 2003-05-20 | Ariad Gene Therapeutics, Inc. | Materials and methods involving conditional retention domains |
| US6306663B1 (en) | 1999-02-12 | 2001-10-23 | Proteinex, Inc. | Controlling protein levels in eucaryotic organisms |
| US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
| US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| AU4328801A (en) | 2000-02-24 | 2001-09-03 | Xcyte Therapies Inc | Simultaneous stimulation and concentration of cells |
| AU2001258093A1 (en) | 2000-05-04 | 2001-11-12 | Mount Sinai Hospital | Molecules that modulate ubiquitin-dependent proteolysis and methods for identifying same |
| PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
| US7208157B2 (en) | 2000-09-08 | 2007-04-24 | California Institute Of Technology | Proteolysis targeting chimeric pharmaceutical |
| EP1322750A4 (en) | 2000-09-08 | 2004-09-29 | California Inst Of Techn | PROTEOLYSIS TARGET DRUG TARGET MEDICINE |
| US7745140B2 (en) | 2002-01-03 | 2010-06-29 | The Trustees Of The University Of Pennsylvania | Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool |
| WO2005002526A2 (en) | 2003-07-01 | 2005-01-13 | President And Fellows Of Harvard College | Method and compositions for treatment of viral infections |
| US7371539B2 (en) | 2003-12-03 | 2008-05-13 | President And Fellows Of Harvard College | Targeted polypeptide degradation |
| EP1765988B1 (en) | 2004-05-27 | 2017-09-20 | The Trustees of The University of Pennsylvania | Novel artificial antigen presenting cells and uses therefor |
| ES2627692T3 (es) | 2010-06-10 | 2017-07-31 | Aragon Pharmaceuticals, Inc. | Moduladores de receptores de estrógenos y usos de los mismos |
| US8853423B2 (en) | 2010-06-17 | 2014-10-07 | Seragon Pharmaceuticals, Inc. | Indane estrogen receptor modulators and uses thereof |
| ES2656414T3 (es) | 2010-09-08 | 2018-02-27 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | Receptores de antígenos quiméricos con una región bisagra optimizada |
| CA2823837A1 (en) | 2010-12-07 | 2012-06-14 | Yale University | Small-molecule hydrophobic tagging of fusion proteins and induced degradation of same |
| JP6053688B2 (ja) | 2011-10-07 | 2016-12-27 | 国立大学法人三重大学 | キメラ抗原受容体 |
| EA029559B1 (ru) | 2011-12-14 | 2018-04-30 | Серагон Фармасьютикалс, Инк. | Фторированные модуляторы рецепторов эстрогенов и их применение |
| AP2014007657A0 (en) | 2011-12-16 | 2014-05-31 | Olema Pharmaceuticals Inc | Novel benzopyran compounds, compositions and uses thereof |
| HK1208875A1 (en) | 2012-01-12 | 2016-03-18 | 耶鲁大学 | Compounds & methods for the enhanced degradation of targeted proteins & other polypeptides by an e3 ubiquitin ligase |
| US20150119435A1 (en) | 2012-05-11 | 2015-04-30 | Yale University | Compounds useful for promoting protein degradation and methods using same |
| SI3401400T1 (sl) | 2012-05-25 | 2019-10-30 | Univ California | Postopki in sestavki za RNA usmerjeno modifikacijo tarčne DNA in za RNA usmerjeno modulacijo prepisovanja |
| US9610332B2 (en) | 2012-07-18 | 2017-04-04 | Massachusetts Institute Of Technology | Compositions and methods for modulating BRD4 bioactivity |
| US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
| DK3553174T3 (da) | 2012-12-17 | 2025-08-04 | Harvard College | Rna-guided modificering af humant genom |
| DK2956175T3 (da) * | 2013-02-15 | 2017-11-27 | Univ California | Kimærisk antigenreceptor og fremgangsmåder til anvendelse deraf |
| US20140315985A1 (en) | 2013-03-14 | 2014-10-23 | Caribou Biosciences, Inc. | Compositions and methods of nucleic acid-targeting nucleic acids |
| US20140273230A1 (en) | 2013-03-15 | 2014-09-18 | Sigma-Aldrich Co., Llc | Crispr-based genome modification and regulation |
| WO2014144155A1 (en) | 2013-03-15 | 2014-09-18 | Regents Of The University Of Minnesota | Engineering plant genomes using crispr/cas systems |
| US9234213B2 (en) | 2013-03-15 | 2016-01-12 | System Biosciences, Llc | Compositions and methods directed to CRISPR/Cas genomic engineering systems |
| BR112015029455A8 (pt) | 2013-05-28 | 2020-03-17 | Astrazeneca Ab | compostos químicos, uso, métodos e composições para prevenção ou tratamento de câncer |
| KR20250012194A (ko) | 2013-06-17 | 2025-01-23 | 더 브로드 인스티튜트, 인코퍼레이티드 | 바이러스 구성성분을 사용하여 장애 및 질환을 표적화하기 위한 crispr-cas 시스템 및 조성물의 전달, 용도 및 치료 적용 |
| WO2014203129A1 (en) | 2013-06-19 | 2014-12-24 | Olema Pharmaceuticals, Inc. | Combinations of benzopyran compounds, compositions and uses thereof |
| WO2014203132A1 (en) | 2013-06-19 | 2014-12-24 | Olema Pharmaceuticals, Inc. | Substituted benzopyran compounds, compositions and uses thereof |
| MX2015016171A (es) | 2013-06-19 | 2016-08-08 | Seragon Pharmaceuticals Inc | Moduladores del receptor de estrogeno de azetidina y usos de los mismos. |
| EA031077B1 (ru) | 2013-06-19 | 2018-11-30 | Серагон Фармасьютикалз, Инк. | Модулятор рецептора эстрогена и его применения |
| HK1221952A1 (zh) | 2013-07-23 | 2017-06-16 | Bayer Pharma Aktiengesellschaft | 作为bet蛋白和极体样激酶的双重抑制剂的取代的二氢吡啶并[3，4-b]吡嗪酮 |
| EP3027604B1 (en) | 2013-07-31 | 2019-02-20 | Zenith Epigenetics Ltd. | Novel quinazolinones as bromodomain inhibitors |
| US20150051208A1 (en) | 2013-08-14 | 2015-02-19 | Boehringer Ingelheim International Gmbh | Pyridinones |
| US9428513B2 (en) | 2013-11-07 | 2016-08-30 | Boehringer Ingelheim International Gmbh | Triazolopyrazine |
| NZ720004A (en) | 2013-11-18 | 2020-03-27 | Forma Therapeutics Inc | Tetrahydroquinoline compositions as bet bromodomain inhibitors |
| AU2014350051A1 (en) | 2013-11-18 | 2016-07-07 | Crispr Therapeutics Ag | CRISPR-Cas system materials and methods |
| US9399640B2 (en) | 2013-11-26 | 2016-07-26 | Incyte Corporation | Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors |
| JP6174811B2 (ja) | 2013-12-11 | 2017-08-02 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | ゲノムの標的改変のための方法及び組成物 |
| MX386422B (es) | 2013-12-20 | 2025-03-18 | Fred Hutchinson Cancer Center | Moléculas efectoras químericas etiquetadas y receptores de las mismas. |
| EP4420663A3 (en) | 2013-12-20 | 2024-10-30 | Novartis AG | Regulatable chimeric antigen receptor |
| JP6351306B2 (ja) | 2014-03-06 | 2018-07-04 | キヤノン株式会社 | 画像処理装置、画像処理装置の制御方法およびプログラム |
| US20160058872A1 (en) | 2014-04-14 | 2016-03-03 | Arvinas, Inc. | Imide-based modulators of proteolysis and associated methods of use |
| MX387318B (es) | 2014-04-14 | 2025-03-18 | Arvinas Operations Inc | Moduladores de la proteólisis basados en imida y métodos de uso asociados. |
| US20170219596A1 (en) | 2014-07-14 | 2017-08-03 | The Regents Of The University Of California | A protein tagging system for in vivo single molecule imaging and control of gene transcription |
| US20160053272A1 (en) | 2014-07-18 | 2016-02-25 | Whitehead Institute For Biomedical Research | Methods Of Modifying A Sequence Using CRISPR |
| US10071164B2 (en) | 2014-08-11 | 2018-09-11 | Yale University | Estrogen-related receptor alpha based protac compounds and associated methods of use |
| CA2966234A1 (en) | 2014-12-15 | 2016-06-23 | Bellicum Pharmaceuticals, Inc. | Methods for controlled elimination of therapeutic cells |
| JP6815318B2 (ja) * | 2014-12-23 | 2021-01-20 | ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド | 二官能性分子によって標的化タンパク質分解を誘導する方法 |
| US9694084B2 (en) | 2014-12-23 | 2017-07-04 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| MA41346A (fr) | 2015-01-12 | 2017-11-21 | Juno Therapeutics Inc | Eléments régulateurs post-transcriptionnels d'hépatite modifiée |
| CA2974367A1 (en) | 2015-01-20 | 2016-07-28 | Arvinas, Inc. | Compounds and methods for the targeted degradation of the androgen receptor |
| CN107708710A (zh) | 2015-03-17 | 2018-02-16 | 嵌合体生物工程公司 | Smart CAR装置,DE CAR多肽,Side CAR及其使用 |
| CN108601764A (zh) | 2015-03-18 | 2018-09-28 | 阿尔维纳斯股份有限公司 | 用于靶蛋白的增强降解的化合物和方法 |
| HRP20220893T1 (hr) | 2015-04-08 | 2022-10-14 | Novartis Ag | Cd20 terapije, cd22 terapije, i kombinirane terapije sa stanicom koja eksprimira cd19 kimerni antigenski receptor |
| US9969792B2 (en) | 2015-06-12 | 2018-05-15 | Axiomx, Inc. | Methods and compositions for producing a chimeric polypeptide |
| WO2017007612A1 (en) | 2015-07-07 | 2017-01-12 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| KR20180035828A (ko) | 2015-07-10 | 2018-04-06 | 아비나스 인코포레이티드 | 단백질 분해의 mdm2계 조절인자 및 관련된 이용 방법 |
| EP3331906A1 (en) | 2015-08-06 | 2018-06-13 | Dana-Farber Cancer Institute, Inc. | Tunable endogenous protein degradation |
| US9809603B1 (en) | 2015-08-18 | 2017-11-07 | Deuterx, Llc | Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same |
| WO2018064589A1 (en) | 2016-09-29 | 2018-04-05 | Dana-Farber Cancer Institute, Inc. | Targeted protein degradation using a mutant e3 ubiquitin ligase |
-
2018
- 2018-02-08 CA CA3053006A patent/CA3053006C/en active Active
- 2018-02-08 JP JP2019542407A patent/JP7227912B2/ja active Active
- 2018-02-08 EP EP18750939.3A patent/EP3580212A4/en not_active Withdrawn
- 2018-02-08 AU AU2018219289A patent/AU2018219289A1/en not_active Abandoned
- 2018-02-08 EP EP22182901.3A patent/EP4119552A1/en active Pending
- 2018-02-08 WO PCT/US2018/017464 patent/WO2018148440A1/en not_active Ceased
- 2018-02-08 US US16/483,204 patent/US11311609B2/en active Active
- 2018-02-08 CN CN201880024542.9A patent/CN111386263A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020505932A5 (enExample) | ||
| Zhang et al. | Bispecific antibody-mediated redirection of NKG2D-CAR natural killer cells facilitates dual targeting and enhances antitumor activity | |
| Flaig et al. | Cutting edge: NTB-A activates NK cells via homophilic interaction | |
| JP2018525006A5 (enExample) | ||
| Müller et al. | A novel antibody–4-1BBL fusion protein for targeted costimulation in cancer immunotherapy | |
| JP2018520679A5 (enExample) | ||
| CA2246352A1 (en) | Methods for inhibiting an immune response by blocking the gp39/cd40 and ctla4/cd28/b7 pathways and compositions for use therewith | |
| JP2020511136A5 (enExample) | ||
| JP2020517295A5 (enExample) | ||
| JP2020513754A5 (enExample) | ||
| JP2019513394A5 (enExample) | ||
| JP2017527275A5 (enExample) | ||
| JP2019501647A5 (enExample) | ||
| JP2020536531A5 (enExample) | ||
| Yu et al. | Identification of a ligand for glucocorticoid-induced tumor necrosis factor receptor constitutively expressed in dendritic cells | |
| CN112154204A (zh) | 基因工程化的细胞及应用 | |
| Xia et al. | CD28: A new drug target for immune disease | |
| Pan et al. | Targeting immune checkpoints in anti-neutrophil cytoplasmic antibodies associated vasculitis: the potential therapeutic targets in the future | |
| IL278245B2 (en) | Auto/Alloimmune Defense Receptors for Mucosal Targeting of Activated Pathogenic T and NK Cells | |
| Choi et al. | The murine CD137/CD137 ligand signalosome: A signal platform generating signal complexity | |
| JPWO2020104676A5 (enExample) | ||
| JPWO2020037066A5 (enExample) | ||
| Bromberg | The biology of CD2: adhesion, transmembrane signal, and regulatory receptor of immunity | |
| JPWO2019172358A5 (enExample) | ||
| Burckhart et al. | Tumor-specific crosslinking of GITR as costimulation for immunotherapy |